Clinical Trial Update: Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of oral PHA-022121 for prophylaxis against angioedema attacks in patients with hereditary angioedema (Types I and II) has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• PHA-022121

Snippet

Sponsor: Pharvaris Netherlands B.V. | Conditions: Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Status: COMPLETED